Finally, when we studied the survival rates of patients with lung cancer with wild-type and mutant genotypes, the patients with EGFR mutation had significantly poorer prognosis than those with wild-type EGFR, indicating an interaction between the EGFR signaling pathway and drug resistance-induced gene mutation. The gene discussed is EGFR; the disease is lung carcinoma.